FDA approves LPI's Perindopril Erbumine tablets

Download PDF Copy

Jan 29 2010

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Perindopril Erbumine tablets, 2mg, 4mg and 8mg. Commercial shipments of the product will commence shortly.

Lupin's Perindopril Erbumine tablets are AB-rated to ACEON®* tablets indicated for the treatment of patients with essential hypertension and can be used with conventional treatment for management of coronary artery disease. ACEON had annual sales of approximately $24 million for the twelve months ended September 2009, based on IMS Health sales data.

SOURCE Lupin Pharmaceuticals, Inc.

Posted in: Medical Condition News | Pharmaceutical News

Tags: Asthma, Coronary Artery Disease, Drug Delivery, Food, Hypertension (High Blood Pressure), Pediatrics, Perindopril, Pharmaceuticals

Comments (0)

Download PDF Copy

Suggested Reading

Updated Food Compass 2.0 improves food health ratings using new diet data

Updated Food Compass 2.0 improves food health ratings using new diet data

Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty

Limiting fast-food outlets can reduce childhood overweight and obesity

Limiting fast-food outlets can reduce childhood overweight and obesity

Ultra-processed food linked to weight gain and lower well-being in adolescents

Ultra-processed food linked to weight gain and lower well-being in adolescents

Six common flying with food allergies myths

Six common flying with food allergies myths

Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group

Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group

Ultra-processed foods increase active psoriasis risk, study shows

Ultra-processed foods increase active psoriasis risk, study shows

Online food shopping: Are you getting the information you need?

Online food shopping: Are you getting the information you need?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Ultra-processed foods dominate children's diets from toddlerhood to middle childhood